Federal Register / Vol. 73, No.
35 / Thursday, February 21, 2008 / Notices
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3180 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 20, 2007
and published in the Federal Register
on November 30, 2007 (72 FR 67759),
Lipomed Inc., One Broadway,
Cambridge, Massachusetts 02142, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in
schedule I:
Drug
Methcathinone (1237) ..................
N–Ethylamphetamine (1475) ........
Gamma Hydroxybutyric Acid
(2010).
2,5-Dimethoxy-4-[n]-
propylthiophenethylamine
(7348).
The company plans to import the
listed controlled substances for clinical
trials, research, analytical purposes, and
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Lipomed Inc. to import the basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Lipomed Inc. to ensure
pwalker on PROD1PC71 with NOTICES
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
VerDate Aug<31>2005 16:34 Feb 20, 2008 Jkt 214001
9591
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above-named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3183 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated August 16, 2007 and
published in the Federal Register on
August 27, 2007 (72 FR 49020), CIMA
Labs, Inc., 10000 Valley View Road,
Attention: Jason Gardner, Eden Prairie,
Minnesota 55344, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Nabilone (7379), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
basic class of controlled substance for
Schedule
clinical trials and research.
I No comments or objections have been
I received. DEA has considered the
I factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
I dimethoxyamphetamine (7395).
CIMA Labs, Inc. to import the basic
class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated CIMA
Labs, Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above-named
company is granted registration as an
importer of the basic class of controlled
substance listed.
PO 00000 Frm 00076 Fmt 4703 Sfmt 4703
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3184 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
September 18, 2007, United States
Pharmacopeial Convention, 12601
Twinbrook Parkway, Rockville,
Maryland 20852, made application to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule I and II:
Drug Schedule
Cathinone (1235) .......................... I
Methaqualone (2565) ................... I
Lysergic acid diethylamide (7315) I
Marihuana (7360) ......................... I
Tetrahydrocannabinols (7370) ..... I
4-Methyl-2,5- I
3,4-Methylenedioxyamphetamine I
(7400).
Codeine-n-oxide (9053) ................ I
Heroin (9200) ............................... I
Amphetamine (1100) .................... II
Methamphetamine (1105) ............ II
Phenmetrazine (1631) .................. II
Methylphenidate (1724) ................ II
Amobarbital (2125) ....................... II
Pentobarbital (2270) ..................... II
Secobarbital (2315) ...................... II
Glutethimide (2550) ...................... II
Phencyclidine (7471) .................... II
Alphaprodine (9010) ..................... II
Anileridine (9020) ......................... II
Cocaine (9041) ............................. II
Codeine (9050) ............................. II
Dihydrocodeine (9120) ................. II
Oxycodone (9143) ........................ II
Hydromorphone (9150) ................ II
Diphenoxylate (9170) ................... II
Hydrocodone (9193) ..................... II
Levorphanol (9220) ...................... II
Meperidine (9230) ........................ II
Methadone (9250) ........................ II
E:\FR\FM\21FEN1.SGM 21FEN1
 9592 Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
Drug
Dextropropoxyphene, bulk (non-
dosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
The company plans to import
reference standards for sale to
researchers and analytical labs.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA. 22152; and must
be filed no later than March 24, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
pwalker on PROD1PC71 with NOTICES
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3178 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005 16:34 Feb 20, 2008 Jkt 214001
Schedule DEPARTMENT OF JUSTICE
II Drug Enforcement Administration
II Importer of Controlled Substances;
II Notice of Registration
II
By Notice dated November 6, 2007
II
and published in the Federal Register
II
on November 16, 2007 (72 FR 64678–
II
64679), Fisher Clinical Services Inc.,
II
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed controlled substance for analytical
research and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Fisher Clinical Services Inc. to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Fisher
Clinical Services Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: February 12, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3171 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on December 10, 2007,
Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\21FEN1.SGM
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Lisdexamfetamine
(1205), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for sale to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Office of Diversion Control, Federal
Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia
22152; and must be filed no later than
April 21, 2008.
Dated: February 13, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–3176 Filed 2–20–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on January 2, 2008,
Siemens Healthcare Diagnostics Inc.,
100 GBC Drive, Mail Stop 514, Newark,
Delaware 19702, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug Schedule
Tetrahydrocannabinols (7370) ..... I
Ecgonine (9180) ........................... II
Morphine (9300) ........................... II
The company plans to produce the
listed controlled substances in bulk to
be used in the manufacture of reagents
and drug calibrator/controls which are
DEA exempt products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
21FEN1